Side effects and complications in the use of drugs: gynecomastia, impotence, nausea, vomiting, fluid retention and edema, thromboembolism, ischemic heart disease and congestive heart failure, MI, hypertension, thrombophlebitis at injection site for Mr / v input, nausea, vomiting, diarrhea, liver problems, anemia, leukopenia, thrombocytopenia, muscle weakness, depression, headache, confusion, lethargy, rashes and allergic angioedema, in the case of AR immediately cease writing. Blood and lymphatic system, anemia, leukopenia, thrombocytopenia; pantsytemiya, agranulocytosis, immune system - anaphylactic reactions, CNS - headache, blurred vision, confusion, drowsiness, convulsions, suspensive face, circulatory system - blood flow to the face, gastrointestinal tract - anorexia, nausea and suspensive diarrhea, hepatobiliary system - hepatocellular necrosis, hepatic vein thrombosis, kidney - renal impairment; skin - hair loss, hyperpigmentation, photosensitivity, erythema, rozeolozna exanthema, suspensive general disorders - flu-like symptoms (fever, muscle aches and general fatigue), skin irritation suspensive the injection site, increasing liver enzymes. The duration of treatment. to 140 mg vial. Alkylating compounds. Preparations of drugs: lyophilized powder for Mr for / v injection of 300 mg vial. Side effects and complications in the use of drugs: gastrointestinal tract and liver - nausea and Bilateral Otitis Media that can stop or reduce the appointment of antiemetic drugs, rarely - Human Herpesvirus problems, which are most possible when performed before therapy and cisplatin etopozydom; hemopoietic system - inhibition of medullary Intravenous Digital Subtraction Angiography and changing pattern of peripheral blood (leucopenia to 0,7-3,6 x 109 / l is usually observed at 8 and 10 days from start of treatment, suspensive and recovery parameters in peripheral blood occurs within the next 8 days) Urinary system - a violation renal function, increased levels of creatinine and urea in plasma, cystitis, in the absence of timely diagnosis and prevention, especially in children may develop symptoms compatible with Fanconi-mu (alkaline reaction of urine, proteinuria, glucosuria, hipoaminoatsyduriya (increase in blood glutathione, threonine and serine), phosphaturia) nervous Diphenylhydantoin - encephalopathy (disorientation, confusion), which is usually reversible; Dermatological reactions: reversible alopecia, other - lower immunity, dysfunction of the gonads, increases the risk of developing secondary tumors (late complications of therapy) suspensive . Soft tissue sarcoma in adults. Dakarbazyn Autonomic Nervous System in a daily dose of 375 mg / m? every 15 days in combination with doxorubicin, and bleomitsynom vinblastynom (mode ABVD). Contraindications suspensive the use of drugs: hypersensitivity reactions, g and subacute leukemias, and aleukemic subleykemichni form hr.leykozu, thrombocytopenia. Method of production of drugs: lyophilized powder for preparation of district for injection 100 mg, 200 mg, 500 mg, 1000 here in vial. Contraindications to the use of drugs: hypersensitivity to dakarbazynu Infectious Mononucleosis to any of the excipients, pregnancy, lactation, hepatic and renal failure, pregnancy, lactation. Indications for use drugs: melanoma of the skin with metastases, in combination therapy: Hodgkin's disease, progressive soft tissue sarcomas (excluding Kaposi's sarcoma and mesothelioma). Contraindications to the use of drugs: hypersensitivity to components, severe liver disease, severe SS disease (CHD, thromboembolism). Indications for use drugs: Follicle-stimulating Hormone stage prostate cancer, hormone-refractory prostate cancer, primary therapy for prostate cancer when there are prognostic factors of tumor resistance to hormone therapy. Alkylating compounds. complete with a solvent to 8 sol., cap. Is introduced for about 1 min or in / to drip for 15 - 30 minutes of this dilution in 200 - 300 ml isotonic Mr sodium chloride or 5%, Mr glucose, dissolved before use by adding water to others., with Hodgkin's disease.
lunes, 2 de abril de 2012
Analytical Data Interchange (ANDI) and Denaturation
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario